Inhalation Anesthesia Market Share, Size, Trends, Industry Analysis Report, By Drug (Sevoflurane, Desflurane, Isoflurane, Others); By Application; By End-Use; By Region; Segment Forecast, 2024 - 2032
- Published Date:Jan-2024
- Pages: 118
- Format: PDF
- Report ID: PM4294
- Base Year: 2023
- Historical Data: 2019 – 2022
Report Outlook
The global inhalation anesthesia market was valued at USD 1.55 billion in 2023 and is expected to grow at a CAGR of 9.2% during the forecast period.
Inhalational anesthetics, also known as volatile anesthetic agents, are used to initiate and maintain general anesthesia and sedation. These anesthetics are especially effective when administered via inhalation because intravenous and alternative routes are impractical. Desflurane, sevoflurane, and nitrous oxide are currently the most commonly used inhalation anesthetics. Primarily, sevoflurane has a rapid onset of action and a rapid recovery rate, which contributes to its widespread use in modern practice.
Several factors are driving the growth of the inhalation anesthesia market. The increasing global prevalence of surgeries, combined with the increasing occurrence of diseases such as cardiac ailments, neurovascular conditions, and other chronic illnesses, will contribute to an increase in demand for various surgical interventions. The respiratory system allows for the safe and cost-effective administration of anesthetics, resulting in a convenient and efficient sedation method. The market is growing due to the numerous advantages of inhalation anesthesia over intravenous anesthesia. Inhalation anesthesia is the preferred choice for patients undergoing ventilation for more than 24 hours, as it simplifies patient monitoring.
To Understand More About this Research: Request a Free Sample Report
The rising prevalence of diseases such as gastrointestinal disorders, respiratory diseases, and cancer are driving the growth of the inhalation anesthesia market. The continuous expansion of research and development in the healthcare industry is anticipated to offer lucrative opportunities for key players in the global market. Due to the presence of advanced healthcare facilities, developed nations such as the United States and Canada have higher healthcare treatment and service costs. The widespread adoption of innovative technologies, fueled by ongoing advancements in healthcare technology, occurs on a daily basis around the world. These scientific and technological advances help to improve disease prevention and recovery methods. Given the wide range of technological innovations supporting various medical domains.
The COVID-19 pandemic has a significant impact on the inhalation anesthesia market. The demand for inhalation anesthesia products, which are commonly used in surgical procedures and medical interventions, was hampered by the prioritization of resources for managing COVID-19 cases. Many elective surgeries were postponed or canceled in order to conserve healthcare resources and reduce the risk of virus transmission. This led to a decrease in the overall utilization of inhalation anesthesia products and equipment.
The use of surgical anesthetics has decreased as the number of non-essential surgeries has decreased. In contrast, hospitals have seen an unprecedented increase in critical care unit (ICU) admissions as a result of the COVID-19 pandemic. According to one study, 5-10% of COVID-19 patients experiencing acute respiratory distress require prolonged critical care (ARDS). These patients typically require large amounts of sedatives and paralytics, which increases the demand for critical care medications such as anesthetics, paralytics, opioids, and vasoactive agents. This increased demand is especially noticeable in ARDS ventilatory strategies. As a result, the impact of COVID-19 on the anesthetic drug industry has been minimal.
The growing global population, particularly among the elderly, has resulted in an increase in the number of people dealing with various health issues, such as cancer, cardiovascular issues, spinal conditions, orthopedic issues, respiratory ailments, gastrointestinal disorders, neurological conditions, and more. This is anticipated to fuel market growth in the forecast period. The surging use of orthopedic procedures such as ligament repairs and other soft tissue interventions is anticipated to play a significant role in the growth of inhalation anesthesia.
Industry Dynamics
Growth Drivers
Increasing number of surgeries will drive the growth of the market
The rising number of surgeries will drive the growth of the inhalation anesthesia market, owing to a surge in the number of road accidents and increase in the number of emergency cases. Along with an increase in the prevalence of various disorders such as cancer, respiratory illnesses, and gastrointestinal issues, as well as an increase in surgical procedures for disease diagnosis, global healthcare is facing significant challenges. Furthermore, the global prevalence of chronic diseases such as cancer, infectious diseases, and genetic abnormalities is increasing. Cancer, according to the World Health Organization (WHO), is a major cause of morbidity and mortality, with nearly 10 million deaths anticipated. This number is expected to rise in the coming decades. Particularly, a large proportion of cancer-related infections occur in low- and middle-income countries.
This drug aid surgeons to avert additional hospital stay of patients due to the relative minimum MAC number of these drugs. Additionally, laparoscopic surgeries are interrelated with low hospital costs than the open surgeries. As a result, patients undergoing minimally invasive surgical procedures have shorter hospital stays and lower rates of readmission.
Report Segmentation
The market is primarily segmented based on drug, application, end-use, and region.
|
By Drug |
By Application |
By End-Use |
By Region |
|
|
|
|
To Understand the Scope of this Report: Speak to Analyst
By Drug Analysis
The sevoflurane segment accounted for the largest revenue share in 2023
In 2023, the sevoflurane segment held the largest revenue share. Sevoflurane differentiates itself in the market owing to its potent and rapid action, which allows for faster emergence and recovery when compared to other drugs. Despite its higher cost, surgeons prefer sevoflurane for the induction and maintenance of anesthesia during surgical procedures.
On the other hand, the isoflurane segment is expected to witness fastest growth during the forecast period. Isoflurane is the favored choice for inhalation general anesthesia amidst anesthesiologists in developing countries such as Indonesia, India, Brazil, and South Africa, owing to its low cost. It is worth noting that isoflurane drugs are approximately two to three times less expensive than sevoflurane, making them a preferred option for cost-conscious patients in these regions.
By End-Use Analysis
The hospital segment accounted for the highest market share during the forecast period
The hospital segment accounted for the highest market share during the forecast period, owing to the more number of surgeries performed. Furthermore, due to the presence of an anesthesiologist and improved patient monitoring services for management, the segment's dominance is anticipated to be sustained over the forecast period. However, European hospitals are working to reduce harmful gas emissions by reducing the use of inhalation anesthesia.
On the other hand, the ambulatory surgical centers are anticipated to witness fastest growth during the forecast period. It creates a dedicated environment for performing surgeries on the same day, necessitating the use of inhalation anesthetics with rapid onset and recovery. Because these patients do not require an overnight stay, inhaled anesthesia has a competitive advantage in the ambulatory surgical center setting.
Regional Insights
North America accounted for the largest market share in 2023
In 2023, North America held the largest market share in the inhalation anesthesia market. The rise in the number of surgeries performed in the United States has been attributed to a variety of factors. Mainly, key industry participants have witnessed significant rise in market revenue within the country. Furthermore, the substantial presence of registered hospitals in the United States plays a crucial role in driving the increased demand for anesthetic drugs during surgical procedures across the region.
Asia Pacific is witnessed for the fastest growth in the inhalation anesthesia market. The growing population in this region has resulted in a significant increase in surgical procedures. The region's growing geriatric population is also a major contributor to the region's rising disease incidence, creating a greater demand for inhaled anesthetic drugs. Also, the widespread use of sevoflurane and desflurane during day surgeries in China is attributed to their advantageous features, such as quick response times and accelerated recovery.
Key Market Players & Competitive Insights
The market is characterized by intense competition, with established players relying on advanced technology, high-quality products, and a strong brand image to drive revenue growth. These companies employ various strategies such as research and development, mergers and acquisitions, and technological innovations to expand their product portfolios and maintain a competitive edge in the market.
Some of the major players operating in the global market include:
- AbbVie Inc.
- Baxter International Inc.
- Dechra Pharmaceuticals PLC (Halocarbon Life Sciences LLC)
- Fresenius Kabi AG (Fresenius SE & Co. KGaA)
- Hikma Pharmaceuticals PLC
- Jiangsu Hengrui Medicine Co. Ltd
- Lunan Pharmaceutical Group Co. Ltd
- Merck KGaA
- Piramal Enterprises Limited
- Troikaa Pharmaceuticals Ltd
Recent Developments
- In February 2022, Sedana Medical AB has launched Sedaconda (isoflurane) in the German market. This product received European DCP approval in July 2021 and national approvals in 14 countries. Within the same year, the company submitted additional marketing approval applications. National approvals for Sedaconda in Italy, Poland, Switzerland, and the United Kingdom are anticipated in 2022.
- In January 2022, Dechra has acquired inhalant anesthetic products, specifically Isoflurane and sevoflurane, from Halocarbon Life Sciences.
Inhalation Anesthesia Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2024 |
USD 1.69 billion |
|
Revenue forecast in 2032 |
USD 3.42 billion |
|
CAGR |
9.2% from 2024 – 2032 |
|
Base year |
2022 |
|
Historical data |
2019 – 2022 |
|
Forecast period |
2024 – 2032 |
|
Quantitative units |
Revenue in USD billion and CAGR from 2024 to 2032 |
|
Segments Covered |
By Drug, By Application, By End-Use, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
|
Customization |
Report customization as per your requirements with respect to countries, region and segmentation |
Browse Our More Top Selling Reports:
Garage Organization and Storage Market Size & Share
Port Equipment Market Size & Share
Inspection Machines Market Size & Share
FAQ's
key companies in inhalation anesthesia market are AbbVie Inc., Baxter International Inc., Dechra Pharmaceuticals PLC (Halocarbon Life Sciences LLC), Fresenius Kabi AG (Fresenius SE & Co. KGaA),
The global inhalation anesthesia market is expected to grow at a CAGR of 9.2% during the forecast period.
The inhalation anesthesia market report covering key segments are drug, application, end-use, and region.
key driving factors in inhalation anesthesia market are increasing number of surgeries will drive the growth of the market
The global inhalation anesthesia market size is expected to reach USD 3.42 billion by 2032
